Core Viewpoint - The company, Foci Pharmaceutical (002644.SZ), is strategically investing in the radioactive isotope drug sector to enhance its core competitiveness by signing a capital increase agreement with Kejin Taiji Technology Co., Ltd. for 20 million yuan, acquiring a 4.911% stake in the company by October 10, 2025 [1] Group 1: Investment Details - The investment amount is 20 million yuan, which will result in a 4.911% equity stake in Kejin Taiji Technology Co., Ltd. after the capital increase [1] - The agreement is aimed at positioning the company in the radioactive isotope drug market, which is expected to grow significantly [1] Group 2: Company Background - Kejin Taiji Technology Co., Ltd. is a wholly-owned subsidiary of the Institute of Modern Physics, Chinese Academy of Sciences, primarily engaged in the design and technical services of ion accelerator systems [1] - The company is involved in the construction of a medical isotope drug research and development platform in Lanzhou New Area, focusing on alpha-emitting isotopes like 225Ac and 223Ra for cancer treatment [1] Group 3: Future Business Focus - Post-investment, Kejin Taiji Technology Co., Ltd. will collaborate with the Institute of Modern Physics and Gansu Isotope Laboratory to produce, sell, and develop medical isotopes and related drugs [1] - The goal is to achieve breakthroughs in the mass production of alpha-emitting isotopes and ensure the autonomy of key technologies and equipment [1]